Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study
- 331 Downloads
The recent release of a medical cannabis strain has given a new impulse for the study of cannabis in Italy. The National Health Service advises to consume medical cannabis by vaporizing, in decoction or oil form. This is the first study that explores the pharmacokinetics and tolerability of a single oral dose of cannabis as decoction (200 ml) or in olive oil (1 ml), as a first step to improve the prescriptive recommendations.
This is a single-center, open-label, two-period crossover study designed to assess the pharmacokinetics and tolerability of oral cannabis administered to 13 patients with medication overuse headache (MOH). A liquid chromatography tandem-mass spectrometry (LC-MS/MS) method was conducted for the quantification of THC, CBD, 11-OH-THC, THC-COOH, THC-COOH-glucuronide, THCA-A, and CBDA. Blood pressure, heart rate, and a short list of symptoms by numerical rating scale (NRS) were assessed.
Decoctions of cannabis showed high variability in cannabinoids content, compared to cannabis oil. For both preparations, THCA-A and CBDA were the most widely absorbed cannabinoids, while THC and CBD were less absorbed. The most important differences concern the bioavailability of THC, higher in oil (AUC0–24 7.44, 95% CI 5.19, 9.68) than in decoction (AUC0–24 3.34, 95% CI 2.07, 4.60), and the bioavailability of CBDA. No serious adverse events were reported.
Cannabis decoction and cannabis oil showed different pharmacokinetic properties, as well as distinct consequences on patients. This study was performed in a limited number of patients; future studies should be performed to investigate the clinical efficacy in larger populations.
KeywordsCannabinoids Oral cannabis Cannabis decoction Cannabis oil Pharmacokinetics Headache
We sincerely thank the staff and patients of Medical Toxicology and Headache Centre of Modena, who made possible the realization of the study.
Compliance with ethical standards
The study was approved by the Ethical Committee of Modena (protocol n. 41/2017) and completed in accordance with the ethical standards of the Helsinki Declaration. Written informed consent was obtained from all patients prior to study participation.
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Harvey DJ (1991) Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR (ed) Biochemistry and physiology of substance abuse, Vol III. CRC Press, Boca Raton, pp 279–365Google Scholar
- 13.Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V (2009) Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. J Mass Spectrom 44:1423–1433CrossRefPubMedGoogle Scholar
- 16.Website: Decreto 9 Novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available at: http://www.gazzettaufficiale.it/eli/id/2015/11/30/15A08888/sg;jsessionid=p1rnwNujUKlqQ5azhAQ95A__.NTC-AS3-GURI2A. Accessed 30 Dec 2017
- 17.Website: Attuazione della legge regionale n. 11 del 17 luglio 2014 e del Decreto Ministeriale 9 novembre 2015 inerenti l’uso medico dei preparati vegetali a base di cannabis sativa. Available at: http://salute.regione.emilia-romagna.it/documentazione/leggi/regionali/dgr-2127-2016/dgr-1250-2016/at_download/file/dgr-1250-2016-cannabis.pdf. Accessed 30 Dec 2017
- 18.Romano LL, Hazekamp A (2013) Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 1:1–11Google Scholar
- 19.Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S (2017) Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab MedGoogle Scholar
- 21.Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G (2017) Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. J Pharm Biomed Anal 150:25–32CrossRefPubMedGoogle Scholar
- 29.Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (2011) Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443–457CrossRefPubMedGoogle Scholar
- 33.De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168:79–102CrossRefPubMedGoogle Scholar
- 35.Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470CrossRefPubMedGoogle Scholar